Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, overpriced on
Target Price
The average target price of FYB.DE is 42.6 and suggests 125% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc